Trial Profile
A Phase III, Randomized, Double-Blind Trial of TMC278 25mg q.d. Versus Efavirenz 600mg q.d. in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Naive HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary) ; Abacavir; Efavirenz; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate; Zidovudine
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms THRIVE
- Sponsors Tibotec Inc
- 11 Apr 2014 Results from a 96-week pooled analysis published in the Clinical Infectious Diseases.
- 10 Dec 2012 The US FDA has approved a prescribing information update for rilpivirine to include 96-week pooled data from ECHO and THRIVE, according to a Janssen Therapeutics media release.
- 03 Dec 2012 Pooled analysis of ECHNO and THRIVE trial results at 96 weeks published in AIDS.